Dr. Reddy's Laboratories settles patent litigation with Schering Corp. and Sepracor Inc.

24 Dec 2008 Evaluate

Dr. Reddy's Laboratories has entered into agreements with Schering and Sepracor which will allow itself to manufacture and market generic versions of the CLARINEX-D 12 Hour and CLARINEX-D* -24 Hour products, with six months marketing exclusivity, and the CLARINEX* REDITABS* product, with six months marketing co-exclusivity, starting in 2012, Dr, Reddy's will also market a generic version of the CLARINEX* 5 milligram tablet six months after the launch of the first generic version of that product.

 

The agreements resolve all pending patent infringement actions filed by Schering and Sepracor against Dr. Reddy's in the U.S. District Court for the District of Mew Jersey. The agreements provide for potential modification of select terms based on certain events and developments. Total U.S. sales for all formulations of CLARINEX® products were $362 million in 2007. CLARINEX is antihistamine and decongestant combination treatment to provide relief of nasal and non-nasal allergy symptoms.

 

crackcrack

Dr. Reddys Lab Share Price

1194.55 -19.40 (-1.60%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.